APLLTD vs LAURUSLABS: Stock Comparison
ALEMBIC PHARMA is the larger company by market capitalisation. ALEMBIC PHARMA shows a lower P/E, a higher dividend yield and lower leverage, while LAURUS LABS shows a higher ROE, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
APLLTD leads 8; LAURUSLABS leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | APLLTD | LAURUSLABS |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | APLLTD | LAURUSLABS |
|---|---|---|
| Live Price | ₹800.5 | ₹1,997.9 |
| Day Change | -3.99% | -2.67% |
| Volume | 1.72 L | 13.94 L |
| 52-Week High | ₹998 | ₹2,065.2 |
| 52-Week Low | ₹635.8 | ₹843 |
| Distance from 52W High | -19.79% | -3.26% |
Valuation
| Metric | APLLTD | LAURUSLABS |
|---|---|---|
| Market Cap | ₹15,73,487.81 L Cr | ₹1.08 L Cr |
| P/E Ratio | 22.65x | 98.77x |
| P/B Ratio | 2.77x | 20.37x |
| EPS | ₹35.27 | ₹5.37 |
| Book Value | ₹288.7 | ₹100.53 |
| Dividend Yield | 1.44% | 0.1% |
Growth
| Metric | APLLTD | LAURUSLABS |
|---|---|---|
| Revenue Growth (TTM YoY) | 4.4% | 5.3% |
| EPS Growth (TTM YoY) | 29.2% | 19.4% |
| Qtr Sales Growth | 15.08% | -13.28% |
| Qtr Profit Growth | -12.49% | -19.92% |
Profitability & Leverage
| Metric | APLLTD | LAURUSLABS |
|---|---|---|
| ROE | 11.4% | 14.1% |
| ROCE | 10.76% | 11.66% |
| Net Margin | 8.98% | 13.76% |
| Operating Margin | 11.13% | 18.67% |
| Debt to Equity | 0.2x | 0.38x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | APLLTD | LAURUSLABS |
|---|---|---|
| Promoter Holding | 69.36%▲ 0.13 pp | 27.47%▼ 0.02 pp |
| FII Holding | 4.18%▼ 0.07 pp | 28%▲ 2.18 pp |
| DII Holding | 15.94%▼ 0.24 pp | 13.74%▼ 0.23 pp |
| Public Holding | 10.01%▲ 0.18 pp | 30.78%▼ 1.93 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ALEMBIC PHARMA and LAURUS LABS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.